X
Xuanzhu Biopharm
An international innovative drug research and development company
About Xuanzhu Biopharm
Xuanzhu Biopharm, an innovative drug subsidiary of Sihuan Pharmaceutical Holdings Group, operates as a clinical-stage biopharmaceutical company with a strategic focus on significant disease areas including oncology, digestive health, and metabolic diseases like non-alcoholic steatohepatitis (NASH). Founded in 2002, the company has established a comprehensive research and development platform to create and commercialize Class 1 drugs, addressing unmet clinical needs in China and globally. The company's business model is centered on the independent R&D, production, and eventual commercialization of its drug pipeline. Xuanzhu Biopharm has been actively pursuing capital, having raised ¥610.5 million ($96 million) in a Series B round in January 2022 and attempting an IPO on the Hong Kong Stock Exchange.
The company's product development strategy is driven by dual R&D platforms in small molecule chemistry and large molecule biologics. This has resulted in a robust pipeline of over ten drug assets, featuring small molecules, monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). A key milestone was achieved in June 2023 when its small-molecule drug, Anaprozole Sodium, received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of duodenal ulcers. This was the first drug approved for marketing by Xuanzhu Biopharm, marking its transition from a pure R&D entity to a commercial-stage company. The market for this drug is substantial, with oral proton pump inhibitors in China representing a nearly RMB 13 billion market.
In its oncology pipeline, Xuanzhu Biopharm is advancing multiple candidates, with a particular focus on breast cancer. Its CDK4/6 inhibitor, Birociclib (XZP-3287), is a significant asset, with a New Drug Application (NDA) accepted by the NMPA for treating advanced breast cancer. The company is also developing XZP-3621 for lung cancer, with an expected regulatory decision in 2025. To bolster its large-molecule capabilities, Xuanzhu Biopharm acquired Beijing Combio Pharmaceutical in 2021, integrating antibody technology platforms. Despite its clinical progress, the company has faced financial challenges, reporting net losses due to the high costs of drug development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 23.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2022 | $84M | $662M | Efung Capital · Zhongji Investment · TJ Capital · SDIC Taikang Trust | ↗ |
| SERIES AOther financing | Aug 2020 | $132M | $530M | State Development & Investment Corporation (SDIC) | — |
Growth signals
Latest recorded traffic for Xuanzhu Biopharm is 200 monthly website visits, down 37.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xuanzhu Biopharm in the Dongcheng District ecosystem
The Xuanzhu Biopharm office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A13 investors entered at this stage
State Development & Investment Corporation (SDIC)- SCSunshine Insurance Group Co
- ECEfung Capital
Zhongji Investment- TCTJ Capital
- STSDIC Taikang Trust
- BCBOC Capital
- SGShaanxi Financial Holding Group
- HMHainan Wanxin Private Equity Fund Management
DNV capital- HFHaichuang Funds of Funds
- HCHuayi Capital
- JIJinjiang Xuanhong Equity Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xuanzhu Biopharm on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xuanzhu Biopharm’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









